Kodiak Gas Services, Inc. (NYSE:KGS) Q3 2024 Earnings Conference Call November 7, 2024 11:00 AM ET Company Participants Graham Sones - Vice President, Investor Relations Mickey McKee - President & Chief Executive Officer John Griggs - Chief Financial Officer Conference Call Participants Doug Irwin - Citi Gabe Moreen - Mizuho John Mackay - Goldman Sachs Neal Dingmann - Truist Securities Jim Rollyson - Raymond James Sebastian Erskine - Redburn Atlantic Theresa Chen - Barclays Zack Van Everen - TPH Operator Gr ...

Financial Data and Key Metrics - Q3 2024 product sales were $8.6 million, exceeding the guided range of $8.3 million to $8.5 million, representing an 11% YoY growth [12] - Product gross margins were 61% for the quarter, above the guided range of 50% to 60%, but down from 71% YoY due to a planned production slowdown and a short-term manufacturing issue [13] - Operating expenses decreased 25% YoY, leading to a 40% reduction in operating loss and lowering cash burn to $2.7 million compared to $5 million in Q2 2024 [14] - Adjusted EBITDA loss improved to $3.5 million from $5.6 million in the prior year, driven by reduced operating expenses [41] - Net loss for the quarter was $2.3 million compared to $9.2 million in the prior year [41] Business Line Performance - CytoSorb, the flagship product, generated $34 million in trailing 12-month sales, with over 0.25 million devices used cumulatively across 76 countries [9] - DrugSorb ATR, an investigational device, has received FDA breakthrough device designation and is under regulatory review in the U.S. and Canada, with decisions expected in 2025 [10][22] - The PuriFi hemoperfusion pump, launched last quarter, has received positive feedback and is expected to drive increased demand for CytoSorb cartridges [33] Market Performance - CytoSorb sales showed strength in international direct sales channels, particularly in Germany, and growing interest in distributor-served geographies [12] - Brilinta, the blood thinner targeted by DrugSorb ATR, enjoys a dominant market share in Canada and a growing 50% share in the U.S. for acute coronary syndrome treatment [17] Strategic Direction and Industry Competition - The company is focused on expanding its international critical care and cardiac surgery business, improving operational efficiencies, and preparing for the potential launch of DrugSorb ATR in North America [34] - DrugSorb ATR has the potential to address a $300 million TAM initially, which could grow to over $1 billion with label expansion to other blood thinner categories [30] - The company is leveraging its manufacturing and commercialization experience from international markets for the expected North American launch [30] Management Commentary on Operating Environment and Future Outlook - Management highlighted the progress in regulatory submissions for DrugSorb ATR and the potential to transform the standard of care for patients with acute coronary syndromes [27][29] - The company expects to return to normalized production levels and product gross margins in Q4 2024 [13] - Management is optimistic about the future growth opportunities, particularly with the potential FDA and Health Canada approvals in 2025 [34] Other Important Information - The company received MDSAP certification, a significant regulatory milestone, enabling compliance with quality management standards in multiple countries, including the U.S. and Canada [23] - The STAR-T trial data showed a favorable benefit-to-risk profile for DrugSorb ATR in patients undergoing CABG surgery within 2 days of Brilinta discontinuation [19][25] - The company has $12.2 million in cash, including $6.5 million in restricted cash, and access to additional milestone-based liquidity through a loan agreement [42][43] Q&A Session Summary Question: FDA submission review process - The FDA review process for DrugSorb ATR is ongoing, with a decision expected in 2025. The company is eligible for priority review due to its breakthrough device designation, which may expedite the process [46][47] Question: Taiwan launch update - Regulatory approval in Taiwan was recently obtained, and the company anticipates accelerated market entry in the coming year [48] Question: Loan proceeds and restricted cash - The $5 million in restricted cash will be released upon FDA acceptance of the marketing application and raising $5 million in new equity, potentially unlocking $10 million in liquidity [49] Question: PuriFi pump program - The PuriFi pump is designed to expand CytoSorb usage globally, particularly in regions without dialysis infrastructure. It is currently in trial phases and has received positive feedback [51][54] Question: Gross margin normalization - The company expects to return to normalized gross margins in Q4 2024, with a long-term goal of achieving 75% to 80% margins for CytoSorb [56][57]

IBEX Limited (NASDAQ:IBEX) Q1 2025 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Michael Darwal - Head-Investor Relations Bob Dechant - Chief Executive Officer Taylor Greenwald - Chief Financial Officer Conference Call Participants David Koning - Baird Operator Thank you for standing by. My name is Hermione, and I will be your conference operator today. At this time, I would like to welcome everyone to IBEX Limited First Quarter 2025 Financial Results Conference Call. All lines h ...

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Molly Aggas - Investor Relations, Dalton Agency A.J. Kazimi - Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Conference Call Participants Operator Good afternoon. And welcome to Cumberland Pharmaceuticals Third Quarter 2024 Financial Report and Company Update. This call is being recorded at the company's request ...

Financial Data and Key Metrics - Consolidated revenue for Q3 2024 increased 6.1% YoY to $92.3 million, driven by growth in Ting and Domains businesses [30] - Tucows Domains revenue grew 5.9% YoY to $64.7 million, with gross margin up 7.8% to $19.8 million [30][34] - Ting revenue increased 19% YoY to $15.3 million, with gross margin up 38% to $11 million [31][34] - Wavelo revenue decreased 9% YoY to $10.1 million, with gross margin down 4.6% to $10 million [31][35] - Adjusted EBITDA for Q3 2024 was $8.7 million, up 94% YoY, driven by profitability improvements in Ting and Domains [37] Business Line Performance - Tucows Domains delivered its seventh consecutive quarter of revenue growth, with domain services revenue up 6% YoY to $64.7 million [11][12] - Wholesale channel revenue for Domains increased 6% YoY to $55 million, with value-added services gross margin up 26% YoY [13] - Retail channel revenue for Domains grew 5% YoY to $9.7 million, with gross margin up 8% YoY [14] - Wavelo's revenue decreased 9% YoY to $10.1 million, primarily due to churn from DISH's Boost subscribers [17][31] - Ting added 1,400 net new subscribers in Q3, growing 21% YoY to nearly 50,000 subscribers [26] Market and Strategic Focus - Ting has shifted focus from market expansion to improving penetration, churn, and ARPU, with plans to stop all new market expansions [7][29] - Ting expects to reach adjusted EBITDA breakeven in 2025, with significant growth in adjusted EBITDA for Tucows overall [9] - Wavelo is focusing on larger telecom prospects, with sales cycles targeting MNOs, MVNOs, and ISPs with complex systems [22] - Tucows Domains continues to invest in platform and infrastructure development, with registry services being a key midterm opportunity [15] Management Commentary on Industry and Outlook - The fiber mid-market has seen little to no common equity transactions in the past year, making it challenging for Ting to secure long-term equity partners [7] - Telecom is entering an era of compounding inefficiency due to convergence, consolidation, and shifting customer needs, creating opportunities for Wavelo's platform [23] - Ting's fiber business is seen as a long-term value driver, with a focus on loading existing footprints and improving operational KPIs [44][45] - The company expects a dynamic environment for small fiber ISPs in 2025, with Ting positioned to benefit from its operational focus [47] Other Important Information - Tucows laid off over 40% of the Ting workforce, reducing cash operating expenses by $22 million, primarily in people costs [6] - The company had $75.2 million in cash and cash equivalents at the end of Q3 2024, with $15.9 million classified as restricted cash [39] - Ting's CapEx spend decreased from $12 million in Q2 to $8.2 million in Q3, with future CapEx expected to be near exclusively success-based [28] - The company repaid $2.5 million on its syndicated loan in Q3, with a leverage ratio of 3.9x [41] Q&A Summary - No live Q&A session was conducted during the call. Shareholders and analysts were invited to submit questions via email, with responses to be posted on the company's website by November 26 [2][49]

Farmer Bros. Co. (NASDAQ:FARM) Q1 2025 Results Conference Call November 7, 2024 5:00 PM ET Company Participants John Moore - President and CEO Vance Fisher - CFO Conference Call Participants Gerry Sweeney - ROTH Capital Eric Des Lauriers - Craig-Hallum Capital Group Operator Good afternoon, and welcome to the Farmer Brothers Fiscal First Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. Earlier today, the company filed its Form 10-Q and issued its fir ...

Golden Entertainment, Inc. (NASDAQ:GDEN) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET Company Participants James Adams - Investor Relations Blake Sartini - Founder, Chairman and Chief Executive Officer Charles Protell - President and Chief Financial Officer Conference Call Participants Barry Jonas - Truist Securities David Bain - B. Riley Securities Jordan Bender - Citizens JMP David Katz - Jefferies Aaron Lee - Macquarie Asset Management John Dickree - CBRE Carlo Santarelli - Deutsche Bank O ...

Superior Industries International, Inc. (NYSE:SUP) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Dan Lee - Senior Vice President and CFO Majdi Abulaban - President and Chief Executive Officer Conference Call Participants Gary Prestopino - Barrington Research Michael Patrick - Ward Prime Executions Operator Thank you for standing by, and welcome. My name is Albert, and I will be your conference operator today. At this time, I would like to welcome everyone to the Superior I ...

PHX Minerals Inc. (NYSE:PHX) Q3 2024 Results Conference Call November 7, 2024 12:00 PM ET Company Participants Stephen Lee - Investor Relations for PHX Minerals Chad Stephens - President and Chief Executive Officer Ralph D’Amico - Executive Vice President and Chief Financial Officer Danielle Mezo - Vice President of Engineering Conference Call Participants Jeff Grampp - Alliance Global Charles Meade - Johnson Rice Operator Greetings, and welcome to the PHX Minerals, Inc. Third Quarter Earnings Conference Ca ...

F&G Annuities & Life, Inc. (NYSE:FG) Q3 2024 Results Conference Call November 7, 2024 9:00 AM ET Company Participants Lisa Foxworthy-Parker - Senior Vice President, Investor & External Relations Chris Blunt - Chief Executive Officer Wendy Young - Chief Financial Officer Conference Call Participants John Barnidge - Piper Sandler Wesley Carmichael - Autonomous Research Maxwell Fritscher - Truist Operator Good morning, ladies and gentlemen, and welcome to the F&G's third quarter earnings call. During the prese ...